Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in P

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. USO
2. SPY
3. TTAN
4. IONQ
5. QCOM
6. IONS
7. ROIV
8. ORCL
9. AAPL
10. HOOD

Go back to Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in P
(NASDAQ: GMAB) Delayed: 33.53 --0 (-0%)
Previous Close $33.53    52 Week High $ 
Open $33.53    52 Week Low $ 
Day High $33.53    P/E N/A 
Day Low $33.53    EPS $ 
Volume 1,732